Akebia Therapeutics' stock is down 28% after a proposed stock offering, with declining Auryxia revenues and significant financial challenges. Vafseo's market launch shows some promise, but it's a ...

CAMBRIDGE, Mass., March 25, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney ...

CAMBRIDGE, Mass., March 06, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA) today announced plans to release its financial results for the fourth quarter and full year ended ...

Akebia Therapeutics (AKBA) came out with a quarterly loss of $0.10 per share versus the Zacks Consensus Estimate of a loss of $0.08. This compares to break-even earnings per share a year ago.

CAMBRIDGE, Mass., March 19, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics ®, Inc. (“Akebia”) (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by ...

Akebia Therapeutics, Inc. has announced the commencement of an underwritten public offering of its common stock, with all shares being offered by the company itself. Akebia plans to give ...

CAMBRIDGE, Mass., March 19, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics ®, Inc. (“Akebia”) (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted ...

The latest price target for Akebia Therapeutics (NASDAQ:AKBA) was reported by Piper Sandler on March 14, 2025. The analyst firm set a price target for $6.00 expecting AKBA to rise to within 12 ...